Michelle D Failla1, Yvette P Conley2, Amy K Wagner3. 1. Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA Health Promotion & Development, School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA Department of Physical Medicine and Rehabilitation, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 3. Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA Department of Physical Medicine and Rehabilitation, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA wagnerak@upmc.edu.
Abstract
BACKGROUND: Older adults have higher mortality rates after severe traumatic brain injury (TBI) compared to younger adults. Brain-derived neurotrophic factor (BDNF) signaling is altered in aging and is important to TBI given its role in neuronal survival/plasticity and autonomic function. Following experimental TBI, acute BDNF administration has not been efficacious. Clinically, genetic variation in BDNF (reduced signaling alleles: rs6265, Met-carriers; rs7124442, C-carriers) can be protective against acute mortality. Postacutely, these genotypes carry lower mortality risk in older adults and greater mortality risk among younger adults. OBJECTIVE: Investigate BDNF levels in mortality/outcome following severe TBI in the context of age and genetic risk. METHODS: Cerebrospinal fluid (CSF) and serum BDNF were assessed prospectively during the first week following severe TBI (n = 203) and in controls (n = 10). Age, BDNF genotype, and BDNF levels were assessed as mortality/outcome predictors. RESULTS: CSF BDNF levels tended to be higher post-TBI (P = .061) versus controls and were associated with time until death (P = .042). In contrast, serum BDNF levels were reduced post-TBI versus controls (P < .0001). Both gene * BDNF serum and gene * age interactions were mortality predictors post-TBI in the same multivariate model. CSF and serum BDNF tended to be negatively correlated post-TBI (P = .07). CONCLUSIONS: BDNF levels predicted mortality, in addition to gene * age interactions, suggesting levels capture additional mortality risk. Higher CSF BDNF post-TBI may be detrimental due to injury and age-related increases in pro-apoptotic BDNF target receptors. Negative CSF and serum BDNF correlations post-TBI suggest blood-brain barrier transit alterations. Understanding BDNF signaling in neuronal survival, plasticity, and autonomic function may inform treatment.
BACKGROUND: Older adults have higher mortality rates after severe traumatic brain injury (TBI) compared to younger adults. Brain-derived neurotrophic factor (BDNF) signaling is altered in aging and is important to TBI given its role in neuronal survival/plasticity and autonomic function. Following experimental TBI, acute BDNF administration has not been efficacious. Clinically, genetic variation in BDNF (reduced signaling alleles: rs6265, Met-carriers; rs7124442, C-carriers) can be protective against acute mortality. Postacutely, these genotypes carry lower mortality risk in older adults and greater mortality risk among younger adults. OBJECTIVE: Investigate BDNF levels in mortality/outcome following severe TBI in the context of age and genetic risk. METHODS: Cerebrospinal fluid (CSF) and serum BDNF were assessed prospectively during the first week following severe TBI (n = 203) and in controls (n = 10). Age, BDNF genotype, and BDNF levels were assessed as mortality/outcome predictors. RESULTS:CSFBDNF levels tended to be higher post-TBI (P = .061) versus controls and were associated with time until death (P = .042). In contrast, serum BDNF levels were reduced post-TBI versus controls (P < .0001). Both gene * BDNF serum and gene * age interactions were mortality predictors post-TBI in the same multivariate model. CSF and serum BDNF tended to be negatively correlated post-TBI (P = .07). CONCLUSIONS:BDNF levels predicted mortality, in addition to gene * age interactions, suggesting levels capture additional mortality risk. Higher CSFBDNF post-TBI may be detrimental due to injury and age-related increases in pro-apoptotic BDNF target receptors. Negative CSF and serum BDNF correlations post-TBI suggest blood-brain barrier transit alterations. Understanding BDNF signaling in neuronal survival, plasticity, and autonomic function may inform treatment.
Authors: João R Gomes; João T Costa; Carlos V Melo; Federico Felizzi; Patrícia Monteiro; Maria J Pinto; Ana R Inácio; Tadeusz Wieloch; Ramiro D Almeida; Mário Grãos; Carlos B Duarte Journal: J Neurosci Date: 2012-03-28 Impact factor: 6.167
Authors: Jordan C Brooks; David J Strauss; Robert M Shavelle; David R Paculdo; Flora M Hammond; Cynthia L Harrison-Felix Journal: Arch Phys Med Rehabil Date: 2013-07-16 Impact factor: 3.966
Authors: Cristiane Ritter; Aline S Miranda; Vinícius Renê Giombelli; Cristiane D Tomasi; Clarissa M Comim; Antonio Lucio Teixeira; João Quevedo; Felipe Dal-Pizzol Journal: Crit Care Date: 2012-12-17 Impact factor: 9.097
Authors: Matthew E Peters; Vani Rao; Kathleen T Bechtold; Durga Roy; Haris I Sair; Jeannie-Marie Leoutsakos; Ramon Diaz-Arrastia; Robert D Stevens; D Scott Batty; Hayley Falk; Christopher Fernandez; Uju Ofoche; Alexandra Vassila; Anna J Hall; Braden Anderson; Edward Bessman; Constantine G Lyketsos; Allen D Everett; Jennifer Van Eyk; Frederick K Korley Journal: Brain Inj Date: 2017-01-31 Impact factor: 2.311
Authors: Raj G Kumar; Jonathan E Rubin; Rachel P Berger; Patrick M Kochanek; Amy K Wagner Journal: Brain Behav Immun Date: 2015-12-17 Impact factor: 7.217